SPRAVATO® REMS
Learn more about the SPRAVATO® REMS program and the steps for becoming and maintaining your certification to treat appropriate patients with SPRAVATO®.
What Is REMS?
A Risk Evaluation and Mitigation Strategy (REMS) manages known or potential risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.
Due to the risks of serious adverse outcomes resulting from sedation, dissociation and respiratory depression caused by SPRAVATO® administration, as well as the risks of abuse and misuse, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS. The SPRAVATO® REMS supports safe and appropriate use for treatment of patients.